Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRIFFIN: D-RVd vs RVd in Newly Diagnosed Multiple Myeloma
NCT02874742Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2016
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Stringent Complete Response. Started Aug 2016; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02874742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02874742.